>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Anti-Bevacizumab Antibodies (recommended for ADA assay) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 0.1 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibodies (recommended for ADA assay) (Cat. No. BEB-Y9, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9 ng/mL.
Demonstration of the specificity of Anti-Bevacizumab Antibodies (recommended for ADA assay) (Cat. No. BEB-Y9) to the bevacizumab.
Measured by its neutrlizing ability in a functional ELISA. Immobilized bevacizumab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Bevacizumab Antibodies (recommended for ADA assay) (Cat. No. BEB-Y9) and Biotinylated Human VEGF 165 (Cat. No. VE5-H82Q0) with a inhibition rate of 62%.
Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 0.1 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibodies (recommended for ADA assay) (Cat. No. BEB-Y9, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9 ng/mL.
Anti-Bevacizumab Antibodies (recommended for ADA assay) (mouse IgG1, Cat. No. BEB-Y9) captured on CM5 chip via anti-mouse antibodies surface, can bind human bevacizumab with an affinity constant of 1.92 nM.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a series of homogeneous CD3 proteins with good bioactivity. They are verified as 1:1 heterodimers by nonreductive electrophoresis and MALS as well.
ACRO screened a few different beads and bring this tightly controlled superparamagnetic microspheres to you. This product can be widely applied for immunocapture, bio panning and flow cytometry.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.
A-Z